3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Fulvestrant
34
Specimen Handling
31
Letrozole
30
Paclitaxel
23
pembrolizumab
19
Carboplatin
19
ribociclib
18
exemestane
18
Capecitabine
17
Trastuzumab
16
Tamoxifen
16
Magnetic Resonance Spectroscopy
16
palbociclib
15
Anastrozole
15
Biopsy
14
trastuzumab deruxtecan
13
abemaciclib
13
pertuzumab
11
Radiotherapy
11
Cyclophosphamide
9
inavolisib
8
elacestrant
8
olaparib
7
Taxes
7
Standard of Care
7
Radiation
7
Mastectomy, Segmental
7
Goserelin
7
130-nm albumin-bound paclitaxel
7
giredestrant
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
RAD1901
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled